Literature DB >> 33679716

Life-Threatening Influenza, Hemophagocytic Lymphohistiocytosis and Probable Vaccine-Strain Varicella in a Novel Case of Homozygous STAT2 Deficiency.

Bishara J Freij1,2, Aidan T Hanrath3, Rui Chen3, Sophie Hambleton3,4, Christopher J A Duncan3,5.   

Abstract

STAT2 is a transcription factor that plays an essential role in antiviral immunity by mediating the activity of type I and III interferons (IFN-I and IFN-III). It also has a recently established function in the negative regulation of IFN-I signaling. Homozygous STAT2 deficiency is an ultra-rare inborn error of immunity which provides unique insight into the pathologic consequence of STAT2 dysfunction. We report here a novel genetic cause of homozygous STAT2 deficiency with several notable clinical features. The proband presented aged 12 months with hemophagocytic lymphohistiocytosis (HLH) closely followed by clinical varicella, both occurring within three weeks of measles, mumps, and rubella (MMR) and varicella vaccinations. There was a history of life-threatening influenza A virus (IAV) disease 2 months previously. Genetic investigation uncovered homozygosity for a novel nonsense variant in STAT2 (c. 1999C>T, p. Arg667Ter) that abrogated STAT2 protein expression. Compatible with STAT2 deficiency, dermal fibroblasts from the child demonstrated a defect of interferon-stimulated gene expression and a failure to mount an antiviral state in response to treatment with IFN-I, a phenotype that was rescued by lentiviral complementation by wild type STAT2. This case significantly expands the phenotypic spectrum of STAT2 deficiency. The occurrence of life-threatening influenza, which has not previously been reported in this condition, adds STAT2 to the list of monogenetic causes of this phenotype and underscores the critical importance of IFN-I and IFN-III to influenza immunity. The development of probable vaccine-strain varicella is also a novel occurrence in STAT2 deficiency, implying a role for IFN-I/III immunity in control of attenuated varicella zoster virus in vivo and reinforcing the susceptibility to pathologic effects of live-attenuated viral vaccines in disorders of IFN-I immunity. Finally, the occurrence of HLH in this case reinforces emerging links to hyperinflammation in patients with STAT2 deficiency and other related defects of IFN-I signaling-highlighting an important avenue for further scientific enquiry.
Copyright © 2021 Freij, Hanrath, Chen, Hambleton and Duncan.

Entities:  

Keywords:  JAK-STAT signaling pathway; hyperinflammation; inborn errors of antiviral immunity; interferon stimulated gene; type I and type III interferon signaling; type I interferon; varicella zoster virus; viral disease

Year:  2021        PMID: 33679716      PMCID: PMC7930908          DOI: 10.3389/fimmu.2020.624415

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  41 in total

1.  Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43.

Authors:  Magdalena Sarasin-Filipowicz; Xueya Wang; Ming Yan; Francois H T Duong; Valeria Poli; Douglas J Hilton; Dong-Er Zhang; Markus H Heim
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

2.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Authors:  Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien
Journal:  Nat Genet       Date:  2013-01-06       Impact factor: 38.330

3.  Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).

Authors:  Nicolas Goulleret; Elodie Mauvisseau; Mélanie Essevaz-Roulet; Mark Quinlivan; Judy Breuer
Journal:  Vaccine       Date:  2010-06-30       Impact factor: 3.641

Review 4.  Host genetics of severe influenza: from mouse Mx1 to human IRF7.

Authors:  Michael J Ciancanelli; Laurent Abel; Shen-Ying Zhang; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2016-01-04       Impact factor: 7.486

5.  Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency.

Authors:  Michael J Ciancanelli; Sarah X L Huang; Priya Luthra; Hannah Garner; Yuval Itan; Stefano Volpi; Fabien G Lafaille; Céline Trouillet; Mirco Schmolke; Randy A Albrecht; Elisabeth Israelsson; Hye Kyung Lim; Melina Casadio; Tamar Hermesh; Lazaro Lorenzo; Lawrence W Leung; Vincent Pedergnana; Bertrand Boisson; Satoshi Okada; Capucine Picard; Benedicte Ringuier; Françoise Troussier; Damien Chaussabel; Laurent Abel; Isabelle Pellier; Luigi D Notarangelo; Adolfo García-Sastre; Christopher F Basler; Frédéric Geissmann; Shen-Ying Zhang; Hans-Willem Snoeck; Jean-Laurent Casanova
Journal:  Science       Date:  2015-03-26       Impact factor: 47.728

6.  IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo.

Authors:  Caroline Sommereyns; Sophie Paul; Peter Staeheli; Thomas Michiels
Journal:  PLoS Pathog       Date:  2008-03-14       Impact factor: 6.823

7.  STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling.

Authors:  Kei-Ichiro Arimoto; Sara Löchte; Samuel A Stoner; Christoph Burkart; Yue Zhang; Sayuri Miyauchi; Stephan Wilmes; Jun-Bao Fan; Jürgen J Heinisch; Zhi Li; Ming Yan; Sandra Pellegrini; Frédéric Colland; Jacob Piehler; Dong-Er Zhang
Journal:  Nat Struct Mol Biol       Date:  2017-02-06       Impact factor: 15.369

8.  Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon.

Authors:  Andrea Reboldi; Eric V Dang; Jeffrey G McDonald; Guosheng Liang; David W Russell; Jason G Cyster
Journal:  Science       Date:  2014-08-08       Impact factor: 47.728

9.  Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2.

Authors:  Christopher J A Duncan; Benjamin J Thompson; Rui Chen; Gillian I Rice; Florian Gothe; Dan F Young; Simon C Lovell; Victoria G Shuttleworth; Vicky Brocklebank; Bronte Corner; Andrew J Skelton; Vincent Bondet; Jonathan Coxhead; Darragh Duffy; Cecile Fourrage; John H Livingston; Julija Pavaine; Edmund Cheesman; Stephania Bitetti; Angela Grainger; Meghan Acres; Barbara A Innes; Aneta Mikulasova; Ruyue Sun; Rafiqul Hussain; Ronnie Wright; Robert Wynn; Mohammed Zarhrate; Leo A H Zeef; Katrina Wood; Stephen M Hughes; Claire L Harris; Karin R Engelhardt; Yanick J Crow; Richard E Randall; David Kavanagh; Sophie Hambleton; Tracy A Briggs
Journal:  Sci Immunol       Date:  2019-12-13

10.  CADD: predicting the deleteriousness of variants throughout the human genome.

Authors:  Philipp Rentzsch; Daniela Witten; Gregory M Cooper; Jay Shendure; Martin Kircher
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  9 in total

Review 1.  Exposing the Two Contrasting Faces of STAT2 in Inflammation.

Authors:  Philip Duodu; Geohaira Sosa; Jorge Canar; Olivia Chhugani; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2022-07-25       Impact factor: 3.657

2.  Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.

Authors:  Qian Zhang; Daniela Matuozzo; Jérémie Le Pen; Qiang Pan-Hammarström; Bertrand Boisson; Paul Bastard; Helen C Su; Stéphanie Boisson-Dupuis; Laurent Abel; Charles M Rice; Shen-Ying Zhang; Aurélie Cobat; Jean-Laurent Casanova; Danyel Lee; Leen Moens; Takaki Asano; Jonathan Bohlen; Zhiyong Liu; Marcela Moncada-Velez; Yasemin Kendir-Demirkol; Huie Jing; Lucy Bizien; Astrid Marchal; Hassan Abolhassani; Selket Delafontaine; Giorgia Bucciol; Gulsum Ical Bayhan; Sevgi Keles; Ayca Kiykim; Selda Hancerli; Filomeen Haerynck; Benoit Florkin; Nevin Hatipoglu; Tayfun Ozcelik; Guillaume Morelle; Mayana Zatz; Lisa F P Ng; David Chien Lye; Barnaby Edward Young; Yee-Sin Leo; Clifton L Dalgard; Richard P Lifton; Laurent Renia; Isabelle Meyts; Emmanuelle Jouanguy; Lennart Hammarström
Journal:  J Exp Med       Date:  2022-06-16       Impact factor: 17.579

Review 3.  Mechanisms of Viral Degradation of Cellular Signal Transducer and Activator of Transcription 2.

Authors:  Sailen Barik
Journal:  Int J Mol Sci       Date:  2022-01-01       Impact factor: 5.923

4.  Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome.

Authors:  Hassan Abolhassani; Nils Landegren; Paul Bastard; Marie Materna; Mohammadreza Modaresi; Likun Du; Maribel Aranda-Guillén; Fabian Sardh; Fanglei Zuo; Peng Zhang; Harold Marcotte; Nico Marr; Taushif Khan; Manar Ata; Fatima Al-Ali; Remi Pescarmona; Alexandre Belot; Vivien Béziat; Qian Zhang; Jean-Laurent Casanova; Olle Kämpe; Shen-Ying Zhang; Lennart Hammarström; Qiang Pan-Hammarström
Journal:  J Clin Immunol       Date:  2022-01-28       Impact factor: 8.542

5.  Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic.

Authors:  Christopher J A Duncan; Morten K Skouboe; Sophie Howarth; Sophie Hambleton; Trine H Mogensen; Anne K Hollensen; Rui Chen; Malene L Børresen; Benjamin J Thompson; Jarmila Stremenova Spegarova; Catherine F Hatton; Frederik F Stæger; Mette K Andersen; John Whittaker; Søren R Paludan; Sofie E Jørgensen; Martin K Thomsen; Jacob G Mikkelsen; Carsten Heilmann; Daniela Buhas; Nina F Øbro; Jakob T Bay; Hanne V Marquart; M Teresa de la Morena; Joseph A Klejka; Matthew Hirschfeld; Line Borgwardt; Isabel Forss; Tania Masmas; Anja Poulsen; Francisco Noya; Guy Rouleau; Torben Hansen; Sirui Zhou; Anders Albrechtsen; Reza Alizadehfar; Eric J Allenspach
Journal:  J Exp Med       Date:  2022-04-20       Impact factor: 17.579

Review 6.  From rare disorders of immunity to common determinants of infection: Following the mechanistic thread.

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  Cell       Date:  2022-08-18       Impact factor: 66.850

7.  Autoantibodies against type I IFNs in patients with critical influenza pneumonia.

Authors:  Qian Zhang; Andrés Pizzorno; Lisa Miorin; Paul Bastard; Adrian Gervais; Tom Le Voyer; Lucy Bizien; Kai Kisand; Anne Puel; Emmanuelle Jouanguy; Laurent Abel; Aurélie Cobat; Sophie Trouillet-Assant; Adolfo García-Sastre; Jean-Laurent Casanova; Jeremy Manry; Jérémie Rosain; Quentin Philippot; Kelian Goavec; Blandine Padey; Anastasija Cupic; Emilie Laurent; Kahina Saker; Martti Vanker; Karita Särekannu; Tamara García-Salum; Marcela Ferres; Nicole Le Corre; Javier Sánchez-Céspedes; María Balsera-Manzanero; Jordi Carratala; Pilar Retamar-Gentil; Gabriela Abelenda-Alonso; Adoración Valiente; Pierre Tiberghien; Marie Zins; Stéphanie Debette; Isabelle Meyts; Filomeen Haerynck; Riccardo Castagnoli; Luigi D Notarangelo; Luis I Gonzalez-Granado; Nerea Dominguez-Pinilla; Evangelos Andreakos; Vasiliki Triantafyllia; Carlos Rodríguez-Gallego; Jordi Solé-Violán; José Juan Ruiz-Hernandez; Felipe Rodríguez de Castro; José Ferreres; Marisa Briones; Joost Wauters; Lore Vanderbeke; Simon Feys; Chen-Yen Kuo; Wei-Te Lei; Cheng-Lung Ku; Galit Tal; Amos Etzioni; Suhair Hanna; Thomas Fournet; Jean-Sebastien Casalegno; Gregory Queromes; Laurent Argaud; Etienne Javouhey; Manuel Rosa-Calatrava; Elisa Cordero; Teresa Aydillo; Rafael A Medina
Journal:  J Exp Med       Date:  2022-09-16       Impact factor: 17.579

Review 8.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

Review 9.  New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.

Authors:  Annalisa Marcuzzi; Erika Rimondi; Elisabetta Melloni; Arianna Gonelli; Antonio Giacomo Grasso; Egidio Barbi; Natalia Maximova
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.